Early Stage

New first-in-class sensory neuron specific pain drug treats pain without risk of addiction

New first-in-class sensory neuron specific pain drug treats pain without risk of addiction


Raised this Round: Raised: $91,600

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type




SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap




Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Monterey, California

Business Type


Neurocarrus, with a valuation of $11.25 million, is raising funds on Wefunder. The company has developed the drug candidate N-001 to provide neuron-specific pain relief without risk of addiction. Neurocarrus’ N-001 is a first-in-class, long-acting aesthetic-like drug that could reduce or avoid opioid use and targets neurons to calm their excessive activity that causes pain. The company is led by an experienced team and has patents issued on exclusively licensed technology in the US and other countries. Paul Blum founded Neurocarrus in October 2017. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $124,000. The campaign proceeds will be used for salaries, contract research organisation services for pre-clinical development, consultants for FDA review, manufacturing, and operations.

Summary Profit and Loss Statement

FY 2023 FY 2022












Net Income



Summary Balance Sheet

FY 2023 FY 2022




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 06/16/2024
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Neurocarrus 10/30/2024 Wefunder $11,250,000 $91,600 SAFE Active RegCF
Neurocarrus 04/17/2019 Wefunder $7,500,000 $341,682 SAFE Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Neurocarrus on Wefunder 2024
Platform: Wefunder
Security Type: SAFE
Valuation: $11,250,000

Follow company

Follow Neurocarrus on Wefunder 2024

Buy Neurocarrus's Deal Report

Neurocarrus Deal Report

Get KingsCrowd’s comprehensive report on Neurocarrus including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Neurocarrus is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Neurocarrus deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge